Loading news...
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 6,086,840 shares, a growth of 27.4% from the December 31st total of 4,779,373 shares. Currently, 13.6% of the shares of the stock are sold short. Based on an average
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase 100,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) shares gapped up prior to trading on Monday after an insider bought additional shares in the company. The stock had previously closed at $16.08, but opened at $17.24. Zenas BioPharma shares last traded at $19.41, with a volume of 337,494 shares. Specifically, CEO Leon O. Moulder, Jr.
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 20,000 shares of the business's stock in a transaction on Friday, January 9th. The shares were acquired at an average price of $16.55 per share, for a total transaction of $331,000.00. Following the completion of the acquisition, the chief executive officer directly
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 30,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was bought at an average cost of $16.30 per share, for a total transaction of $489,000.00. Following the acquisition, the chief executive officer directly owned 346,155
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) CEO Leon Moulder, Jr. bought 50,000 shares of the firm's stock in a transaction on Wednesday, January 7th. The shares were bought at an average cost of $16.38 per share, with a total value of $819,000.00. Following the purchase, the chief executive officer directly owned 316,155 shares
The Benzinga Stock Whisper Index highlights five stocks seeing stronger than normal interest from readers and looks at the potential catalysts driving the attention.
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Zenas BioPharma tanks nearly 52% despite positive INDIGO study data where obexelimab cut IgG4-RD flare risk by 56% and met all key endpoints.
Zenas BioPharma (NASDAQ: ZBIO) shares fell more than 50% in the last trading session following the release of Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease (IgG4-RD).
Zenas BioPharma remains a 'Strong Buy' after Obexelimab met the phase 3 INDIGO primary endpoint in IgG4-RD, despite a sharp stock decline. The company's pipeline is advancing with Orelabrutinib, a potential best-in-class BTK inhibitor, and multiple phase 3 MS trials underway or planned. Obexelimab offers competitive advantages over UPLINZA, including a differentiated MOA and self-administered SC dosing, targeting elderly IgG4-RD patients.
Zenas BioPharma (NASDAQ: ZBIO) reported top-line results from its registrational phase III INDIGO trial evaluating obexelimab for immunoglobulin G4-related disease (IgG4-RD), saying the study met its primary endpoint and all four key secondary endpoints with "high statistical significance." Company executives also highlighted a safety profile they described as consistent with prior obexelimab studies and favorable versus